Review article: Diabetes and atherosclerosis - Running on a common road

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 22, Issue 2, 2005, Pages 11-15

  Federici, M ^a   Lauro, R ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEXOSAMINE; METALLOPROTEINASE; METALLOPROTEINASE 2; METALLOPROTEINASE 9; SORBITOL; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GENETIC DISORDER; GENETICS; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN RESISTANCE; MATURITY ONSET DIABETES MELLITUS; METABOLIC SYNDROME X; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOKING;

EID: 27644493203     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02617.x     Document Type: Review

References (23)

1. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-8.
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
7. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999; 103: 931-43.
8. Federici M, Menghini R, Hribal ML, et al. Insulin-dependent activation of eNOS is impaired by O-linked-glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 2002; 106: 466-72.
9. Miele C, Riboulet A, Maitan MA, et al. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. J Biol Chem 2003; 278: 47376-87.
10. Beguinot F, Haring H, Kiess W, et al. The search for NIDDM genes project: a European community programme aimed to facilitate the identification of NIDDM genes. Diabetologia 1998; 41 (Suppl.): 15-6.
11. Imai Y, Fusco A, Suzuki Y, et al. Variant sequences of insulin receptor substrate-1 in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994; 79: 1655-8.
12. 972Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic β cells. J Clin Invest 1999; 104: 357-64.
13. 972 amino acid polymorphism in IRS-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab 2000; 85: 2004-13.
14. 972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. FASEB J 2001; 15: 22-4.
15. 972 IRS-1 polymorphism. Diabetes 2002; 51: 1419-24.
16. Federici M, Pandolfi A, De Filippis EA, et al. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 2004; 109: 399-405.
17. Federici M. The strange case of G972R IRS-1 variant and diabetes. Do type 1 and type 2 diabetes share common genes? Mol Genet Metab 2004; 81: 261-2.
18. Marini MA, Frontoni S, Mineo D, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 3368-71.
19. Perticone F, Sciacqua A, Scozzafava A, et al. Impaired endothelial function in never-treated hypertensive subjects carrying the arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 2004; 89: 3606-9.
20. Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001; 88: 1291-8.
21. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-8.
22. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-90.
23. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-8.